Table 2. Multivariate logistic regression analysis to investigate the risk factors for herpes zoster in the patients who received R-CHOP/R-CEOP and CHOP/CEOP.
| CHOP/CEOP (n=2188) |
R-CHOP/R-CEOP (n=1677) |
||||||
|---|---|---|---|---|---|---|---|
| n | OR (95% CI) | P-value | n | OR (95% CI) | P-value | ||
| Gender | Male (ref.) | 1297 | 1 | 913 | 1 | ||
| Female | 891 | 1.53(1.18–1.99) | 0.001 | 764 | 1.44(1.08–1.93) | 0.014 | |
| Age (years) | ≤50 (ref.) | 1029 | 1 | 517 | 1 | ||
| 51–64 | 608 | 0.92(0.68–1.25) | 0.595 | 546 | 1.38(0.97–1.98) | 0.076 | |
| ≥65 | 551 | 0.63(0.44–0.89) | 0.009 | 614 | 0.93(0.63–1.36) | 0.699 | |
| Multiple C/T | No (ref.) | 1452 | 1 | 1265 | 1 | ||
| Yes | 736 | 1.50(1.13–1.99) | 0.005 | 412 | 1.73(1.25–2.38) | 0.001 | |
| Auto-HSCT | No (ref.) | 2119 | 1 | 1635 | 1 | ||
| Yes | 69 | 3.67 (2.14–6.28) | <0.001 | 42 | 2.15(1.05–4.41) | 0.037 | |
| DM | No (ref.) | 1569 | 1 | ||||
| Yes | 108 | 1.78(1.06–2.99) | 0.031 | ||||
| R dose(mg) | ≤3500 (ref.) | 764 | 1 | ||||
| ≥3501 | 913 | 1.58(1.17–2.14) | 0.003 | ||||
OR, odds ratio; 95%CI, 95% confidence interval; CHOP, cyclophosphamide, doxorubicin, vincristine, prednisolone; CEOP, cyclophosphamide, epirubicin, vincristine, prednisolone; Multiple C/T, multiple courses of chemotherapy; Auto-HSCT, autologous hematopoietic stem cell transplantation; DM, diabetes mellitus; R, rituximab.